Cell Cure Neurosciences Ltd.

Neurodegenerative diseases and human embryonic stem cells

Initialy established as subsiduary of ES Cell International in 2005, Cell Cure Neurosciences is today jointly owned by ES International and Hadasit Bio-Holdings Ltd.
The company operates within the facilities of the Hadassah University Hospital, Israel.

Charles S. Irving, Ph.D., COO and General Manager
Benjamin Reubinoff, Prof., CSO

Alan Coleman, Dr.
Raphael Hofstein, Dr.

Phone: +972-545-245-677
Fax: +972-2-642-9856

The concept of Cell Cure Neurosciences is to use human embryonic stem cells (hESCs) for the treatment of neurodegenerative diseases such as Parkinson’s disease, ALS and Alzheimer’s disease. Cell Cure concentrates on the differentiation of hESCs into neural progenitor cells, which could substitute defective brain cells of patients suffering from Parkinson’s disease.

The studies are in pre-clinical stage now. Neural progenitor cells have been tested in a rat model for Parkinson’s disease. Further investigations will concentrate on a monkey model.